Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aliskiren HCTZ vs Amlodipine in African American Patients with Stage 2 Hypertension
NCT00739596Phase 4Completed
- Sponsor
- Novartis
- Start
- Jul 2008
- Primary completion
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of aliskiren in hypertension (HTN) (2 arms), sponsored by Novartis. Primary endpoint: Change in Mean Sitting Systolic Blood Pressure at 8 weeks. Started Jul 2008; status: completed.
02
Drugs
aliskiren
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT00739596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00739596.